Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $46.83 Consensus Price Target from Brokerages

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have been given a consensus rating of “Buy” by the ten analysts that are covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $52.14.

Several analysts have commented on DNTH shares. Wedbush restated an “outperform” rating and issued a $36.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. TD Cowen started coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They issued a “buy” rating for the company. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Guggenheim restated a “buy” rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th.

Dianthus Therapeutics Trading Up 0.2 %

Dianthus Therapeutics stock opened at $21.33 on Wednesday. The firm has a 50-day moving average of $22.54 and a 200-day moving average of $24.81. The firm has a market cap of $631.30 million, a P/E ratio of -8.53 and a beta of 1.82. Dianthus Therapeutics has a 1-year low of $18.13 and a 1-year high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. The company had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Research analysts forecast that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

Large investors have recently made changes to their positions in the business. R Squared Ltd purchased a new position in shares of Dianthus Therapeutics during the fourth quarter valued at approximately $26,000. Quest Partners LLC increased its position in shares of Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after acquiring an additional 1,124 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Dianthus Therapeutics during the fourth quarter valued at approximately $33,000. KBC Group NV bought a new stake in shares of Dianthus Therapeutics during the fourth quarter valued at approximately $35,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Dianthus Therapeutics during the fourth quarter valued at approximately $59,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.